KU Hematology & Medical Oncology Review 2019
KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox for Relapsed/Refractory Disease & Concurrent Rituximab with Cladribine for 1st Line
Login to view comments.
Click here to Login